Immunovant IMVT 深 滬
等待開盤 11-04 09:30:00 美东时间
29.04
+0.630
+2.22%
華盛通- 最 高29.48
- 今 開28.70
- 成交量 107.98万股
- 最 低 28.42
- 昨 收 28.41
- 總市值 59.98亿
- 52周最高 45.42
- 市盈率 靜 --
- 換手率 0.52%
- 52周最低 21.86
- 委 比 -83.33%
- 總股本 2.07亿
- 歷史最高 53.75
- 量 比 0.88
- 振 幅 3.73%
- 歷史最低 3.145
- 每 手 1
- 風險率 6.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
Immunovant, Inc. announced it will report its second fiscal quarter financial results for the period ended September 30, 2026 on November 9, 2026 before market open. Roivant Sciences Ltd., Immunovant's majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that day, including a business update for Immunovant. Registration details and webcast information are available on the Immunovant website. Immunovant is a clinical-...
10-21 11:00
Roivant Sciences added to Citi's 90-day catalyst watch
Citi has added Roivant Sciences (ROIV) to its 90-day positive catalyst watch due to a release of topline data from the phase 3 CLARITY trial for brepocitinib in non-infectious uveitis coming later thi...
10-13 22:56
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 450 points on Thursday. Shares of argenx SE – ADR (NASDAQ:ARGX) fell sharply in pre-market trading after the company announced plans to discontinue Phase 3 UNITY study of efgartigimod subcutaneous in adults with moderate...
10-08 20:07
Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Applied Digital Corp (NASDAQ:APLD) rose sharply in pre-market trading after the company posted better-than-expected financial results for the first quarter. Applied Digital reported first-quarter adjusted revenue of $300.39 million, beating analyst estimates of $132.16 million, according t...
10-08 16:32
Immunovant Ends Autoimmune Skin Disorder Program
Roivant Sciences Ltd. (NASDAQ:ROIV) announced that Immunovant Inc. (NASDAQ:IMVT) plans to halt the development of IMVT-1402 as a treatment for cutaneous lupus erythematosus (CLE). The decision follows recent proof-of-concept trial results that failed to reach statistical significance. Shares of both...
09-23 21:03
Roivant And Immunovant Say Topline Results From Period 1 Of Proof-of-concept Trial of IMVT-1402 (Imeroprubart) For Cutaneous Lupus Erythematosus Did Not Achieve Statistical Significance On The Primary Endpoint
Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12 Positive...
09-23 19:05
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant's IMVT-1402 failed to meet the primary endpoint in a Phase 1 CLE trial, showing no statistical significance in CLASI-A score reduction. While positive trends were observed, development in CLE will halt due to the competitive landscape. The drug demonstrated good safety, and trials in other autoimmune diseases continue.
09-23 11:00
近30亿美元，礼来买下一家刚成立的抗体公司
（来源：抗体圈） 刚刚，礼来公司宣布以最高28.75亿美元现金收购Merida Biosciences。 这家总部位于马萨诸塞州剑桥的生物技术公司，去...
09-01 16:32
财报速睇 | Immunovant 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损1.53亿美元，同比亏损扩大27.0%
华盛资讯8月6日讯，Immunovant公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损1.53亿美元，同比亏损扩大27.0%。
08-06 21:49
